Cigarettes constitute 90% of all combustible tobacco smoke products consumed in the United States and are the single most important cause of avoidable diseases.
The Penn State TCORS will evaluate the feasibility of switching smokers from their usual cigarettes to reduced-nicotine content cigarettes on nicotine dependence and tobacco harm. If safe and effective, this strategy will have large public health benefits.
The overall goal of Penn State TCORS is to develop a leading state-of-the-art research and training infrastructure that will inform policy on the regulation of tobacco products. To achieve these goals, we are uniting the resources of Penn State College of Medicine with Pennsylvania State University, State College, Harvard University and George Washington University.
A number of Penn State’s facilities will be utilized to foster innovative research and training, including a newly built smoking laboratory, MRI labs, and our NIH-funded Clinical &Translational Science Institute. TCORS allows us to add additional expertise, such as a Smoking Biomarkers Core Laboratory that will perform specialized assays for tobacco science for all TCORS. A central theme of our TCORS is the study of tobacco regulatory science in vulnerable (e.g. low socioeconomic status, mental disorders) and minority populations. This will be accomplished through three complementary research projects that share common methodologies, common core multidisciplinary approaches, and common leadership with the overarching aim of relevancy for tobacco regulatory policies.